Ketamidor

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ketamidor

Property Description
Active Ingredient Ketamine
Form Solution for Injection
Pharmacological Class Dissociative Anesthetic
Origin Synthetic Cyclohexanone Derivative
Type Single-ingredient Product

Defining Ketamidor: A Nonbarbiturate Dissociative Anesthetic

Ketamidor is the commercial designation for a medicinal product containing the active substance Ketamine, a drug clinically recognized for its anesthetic properties and its use as a general anesthetic. Specifically, it functions as a nonbarbiturate dissociative anesthetic, belonging to the synthetic cyclohexanone derivative class. The drug is supplied as a clear, colorless solution for injection intended for parenteral administration, formulated as a single-ingredient product containing the racemic mixture of its two isomers. This specialized formulation is utilized when a rapid and predictable onset of action is required for medical procedures.

The General Role of Ketamine

The general purpose of Ketamidor is directly related to its function as an N-methyl-D-aspartate (NMDA) receptor antagonist, which provides a controlled state of profound analgesia (pain relief) and amnesia necessary for medical interventions. This characteristic profile ensures that the drug facilitates a wide array of surgical and diagnostic procedures. Its action provides potent pain relief while often permitting the preservation of spontaneous respiration, a trait that minimizes generalized respiratory depression. This profile makes it valuable for controlled consciousness and immobility while maintaining essential protective reflexes.

Regulatory References

  1. National Library of Medicine (NIH)
  2. MedlinePlus

What side effects are possible with Ketamidor?

The official safety profile for Ketamidor (Ketamine) details specific adverse reactions and contraindications established by regulatory authorities.

Adverse Reaction Scope

The most common and frequently documented adverse effects involve the Cardiovascular system, characterized by a transient increase in blood pressure and heart rate. Psychiatric disorders are also common, particularly the emergence reactions that may occur during recovery, which include vivid dreams, confusion, and hallucinations. Less frequent but documented effects include nausea, vomiting, diplopia, and involuntary eye movements (nystagmus).

Serious Adverse Reactions Regulatory documents list several serious adverse reactions, primarily related to the Respiratory system, such as respiratory depression and laryngospasm, which require immediate management. Other serious risks include significant hypertension that poses a hazard and the official recognition of the drug’s potential for Abuse and Dependence (a controlled substance classification).

Safety Considerations and Restrictions

Safety constraints are defined for certain patient populations. The medication is contraindicated in individuals for whom a substantial rise in blood pressure would be a serious medical risk, such as those with severe, uncontrolled hypertension or eclampsia. Caution is also noted for patients with pre-existing cardiac conditions or increased pressure within the eye or brain (intraocular or intracranial pressure).

Time-Related Patterns While emergence reactions are generally confined to the recovery period, specific safety notes address long-term exposure. Regulatory documentation reports that chronic or extended use is associated with the potential for genitourinary issues (e.g., cystitis and bladder symptoms) and signs of drug-induced liver injury.

Overdose and Emergency Response

Ketamidor Overdose and When to Seek Help

The information in this section is derived strictly from official government regulatory documents (such as the FDA Prescribing Information and EMA Summary of Product Characteristics) and addresses the management of overexposure to Ketamidor.

Documented Overdose Manifestations

Overdose with Ketamidor is officially associated with an mathbfextended duration of anesthetic effects and a mathbfprolonged recovery period. The most mathbfsevere outcomes involve the mathbfCentral Nervous System and mathbfRespiratory System.

  • Respiratory: mathbfRespiratory depression, potentially leading to mathbfapnea (cessation of breathing).
  • Cardiovascular: Changes in heart function, including mathbfhypertension (high blood pressure) and mathbftachycardia (rapid heart rate).

Required Emergency Actions

The official regulatory documents specify that mathbfimmediate emergency medical help must be sought upon any suspected overdose or the observation of severe manifestations, particularly mathbfapnea or mathbfprolonged loss of consciousness. Contacting Emergency Medical Services or a Poison Control Center is required immediately.

Official Management Strategy

Treatment for Ketamidor overdose is mathbfsupportive and symptomatic only. There is mathbfno specific pharmacological antidote for this substance. mathbfPrimary management focuses on:

  • Airway and Ventilation: Ensuring mathbfadequate ventilation and mathbfmaintaining a patent airway; assisted ventilation may be necessary.
  • Monitoring: Continuous mathbfcardiac monitoring and mathbfmonitoring of vital functions must be maintained until the patient is stable.

These measures are required to manage the mathbflife-mathbfthreatening risks associated with overexposure.

Therapeutic Uses of Ketamidor

What Ketamidor Treats: Main Uses and Benefits

The primary role of Ketamidor (Ketamine) is situated across several acute and specialized therapeutic domains. The medication is commonly used to help manage symptom clusters that may become intense or disruptive in conditions presenting with acute episodes.

It is relevant for easing symptoms and providing support across three main categories: general anesthesia and procedural sedation, management of severe acute and intractable chronic pain, and supporting treatment-resistant mood disorders and acute psychiatric crises. It assists with maintaining functional stability during symptomatic periods.

This supportive function is crucial in settings where pain or distress are overwhelming. The aim is symptomatic relief:

“It supports the patient during difficult episodes by easing distress.”

In surgical and procedural contexts, it helps address symptoms related to heightened physiological activity, and may assist in enabling patients to undergo necessary medical interventions. When managing pain, Ketamidor is applied when other supportive measures may be utilized, assisting with conditions characterized by periods of heightened symptoms.


Quick Fact: Relief for Severe Discomfort Ketamidor is considered relevant for easing high-intensity pain and profound emotional distress when symptoms escalate temporarily and short-term symptomatic assistance is needed.

Regulatory References

  1. National Institutes of Health (NIH) StatPearls overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Ketamidor?

Eligibility for Ketamidor is determined by the patient's pre-existing health conditions and age, according to official regulatory documentation. It is an anesthetic agent approved for use in both adults and children, but its use is subject to specific restrictions.

Contraindications (Must Not Use)

Ketamidor is absolutely contraindicated for patients with conditions where a significant elevation of blood pressure would pose a serious hazard. This includes individuals with severe uncontrolled hypertension, severe coronary or myocardial disease, or a history of cerebrovascular accident (stroke). It must also not be used in patients with a known hypersensitivity to the drug.

Age-Specific and Conditional Restrictions

Population Group Eligibility Status Key Restriction (Label-Based)
Adults & Elderly Approved Use in the elderly is associated with the lowest incidence of psychological emergence phenomena.
Children leq 3 years Conditional Use Not recommended for procedures exceeding 3 hours due to a specific regulatory warning about potential neurotoxicity.
Pregnancy/Lactation Not Recommended Safe use in human pregnancy or during breastfeeding has not been established.
Psychiatric Conditions Caution/Restriction Use requires extreme caution or may be prohibited in patients with a history of acute psychosis or schizophrenia.

Use is also required with caution in patients with elevated intracranial pressure or globe injuries.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Regulatory documentation describes interactions with Ketamidor (Ketamine) based on chemical incompatibility, pharmacodynamic synergy, and pharmacokinetic effects.

Pharmacodynamic and Chemical Interactions

Interacting Agents Officially Documented Interaction Pattern
CNS Depressants (e.g., Opioids, Benzodiazepines, Alcohol) Increases the risk of profound sedation, respiratory depression, coma, and death; also prolongs the time to complete recovery.
Sympathomimetics (e.g., Vasopressin) Enhances the pressor effects, which may lead to an increased risk of hypertension and tachycardia.
Theophylline or Aminophylline Concomitant use may lower the seizure threshold.
Barbiturates (e.g., Thiopentone) Chemical incompatibility; must not be mixed in the same syringe or intravenous fluid due to precipitate formation.

Pharmacokinetic Interactions (Enzyme-Mediated)

The metabolism of Ketamidor involves CYP3A4 and CYP2B6 enzymes, resulting in altered systemic exposure when co-administered with modulators:

  • Enzyme Inducers (e.g., Rifampin, St. John's wort) reduce exposure and may lessen the clinical effectiveness of Ketamidor.
  • Enzyme Inhibitors (e.g., Ketoconazole, Grapefruit Juice) increase systemic exposure, potentially enhancing side effects.

Population-specific caution is also noted for patients with liver impairment, as reduced clearance may lead to a prolonged duration of action.

Mechanism of Action

Ketamidor's mechanism is initiated by its selective and allosteric modulation of the A M2 receptor, which is expressed in osteocytes and osteoblasts. This receptor interaction induces a concentration-dependent inhibition of GSK-3beta (Glycogen Synthase Kinase 3beta) enzymatic activity. The resulting deactivation of GSK-3beta stabilizes the beta-catenin protein within the cytoplasm, thereby modulating the canonical Wnt/beta-catenin signaling pathway.

Downstream, this signaling cascade leads to changes in gene transcription. Specifically, it promotes an increase in osteoprotegerin ( O PG) expression while concurrently mediating a reduction in RANKL (Receptor Activator of Nuclear Factor kappa B Ligand) levels. The GSK-3beta inhibition also contributes to the stabilization of cellular energy production. The system-level consequence is the rebalancing of osteoclastogenesis (bone resorption) and osteoblastogenesis (bone formation), thus controlling the rate of bone remodeling. This action also mediates the reduction of CTX (C-terminal telopeptide), a marker of bone turnover.

Dosage and Administration Information

How to Use Ketamidor: Official Administration Guidelines

Ketamidor (Ketamine Solution for Injection) is used exclusively in controlled clinical settings and is administered by or under the direct supervision of physicians experienced in general anesthesia. The medicine is used acutely and is not described in terms of daily or long-term treatment cycles.


Administration Scope

Feature Description
Route of Administration Administered parenterally via Intravenous (IV) Injection, Intramuscular (IM) Injection, or Continuous Intravenous Infusion.
Dosing Schedule IV Induction: Typical initial dose range is 1 mg/kg to 4.5 mg/kg of body weight. IM Induction: Initial dose range is 6.5 mg/kg to 13 mg/kg.
Maintenance Dose Increments of one-half to the full induction dose may be repeated as needed (PRN), or maintained via IV infusion at 10 to 45 mcg/kg/min.
Preparation Requirements The 100 mg/mL concentration must be diluted prior to IV administration, typically with normal saline or 5% dextrose. Use of an antisialagogue is often advised pre-procedure.
Age-Group Rules The drug is suitable for use in pediatric patients. Specific IV doses (0.2 to 1.0 mg/kg) are also noted for use in obstetrics (vaginal delivery or Cesarean section).
Special Procedural Conditions IV bolus doses must be administered slowly over a period of 60 seconds to comply with standard procedural requirements.

Instruction Classifications (High-Level)

Classification Parameter
Administration Method Type Parenteral (Injection, Infusion)
Frequency Pattern As-needed (PRN) for maintenance; Acute procedural use.
Guideline Basis Clinical Administration Standards
Use-Context Constraints Mandated administration in a controlled clinical setting with specialized supervision.

Resulting Procedural Structure

Official Step Sequence (High-Level):

  • Dilution of the concentrated solution is required for intravenous delivery.
  • The calculated, weight-based induction dose is administered, with the IV route mandating injection over a minimum of 60 seconds.
  • Maintenance is achieved through strictly controlled, intermittent re-injection or continuous infusion to sustain the required procedural state.

Connection to the overall use protocol:

The official instructions define a standardized protocol centered on accurate dosing, the choice between intramuscular or slow intravenous administration, and specific preparation steps. This structure ensures that delivery aligns with the established requirements for an anesthetic agent. The larger the total dose administered, the longer the expected time to full recovery.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Ketamidor


Evidence for Use in General Anesthesia and Procedural Sedation

The research base for Ketamidor in this area is extensive, drawing from many Randomized Controlled Trials (RCTs) and systematic reviews conducted over several decades. This body of work has evaluated Ketamidor in the research context of dissociative anesthesia and procedural sedation during a variety of surgical, diagnostic, and emergency procedures. Study designs measured key physiological outcomes, including achieving the required anesthetic state and monitoring physiological strain, particularly outcomes related to the preservation of spontaneous respiration.

The findings describe patterns observed in the studies related to achieving the required anesthetic state. Research highlights the rapid onset and limited duration of observed change. What remains uncertain relates mainly to optimization rather than primary use. Research is ongoing to define the optimal dose and administration protocols for continuous infusions, particularly when used for extended periods in critically ill patients.


Evidence for Use in Severe Acute and Intractable Chronic Pain

Ketamidor was studied in research exploring short-term symptom changes for conditions associated with acute or disruptive episodes, as well as intractable chronic conditions marked by functional limitations. Studies explored changes in outcomes related to physical discomfort, often utilizing patient-reported outcomes describing perceived discomfort via standardized pain intensity scales. A key outcome research examined was the change in the measured outcomes related to the need for analgesic medications.

Research highlights changes measured during the study period for acute pain, with findings describing patterns observed in the studies related to measurements of physical discomfort in acute settings. For chronic pain, studies explored short-term symptom changes, with some research reporting observations of these patterns persisting for up to approximately 3 months. Follow-up durations were limited in many studies focusing on sustained pain measurements.


What Research Gaps Remain

Despite the extensive research across multiple domains, several key areas of uncertainty persist. Long-term effects are not fully established, particularly the sustained functional outcomes for chronic pain and mood disorders that extend beyond a few months. Research is needed to determine how various dosing regimens compare against each other in critical care settings. Additionally, evidence quality varies across studies, particularly for chronic and off-label uses, where studies often have limited follow-up durations or modest sample sizes.

Key Studies & References

  1. Ketamine: National Center for Biotechnology Information (NCBI) Bookshelf Monograph
  2. Ketamine Drug Information: MedlinePlus
  3. Ketamine: StatPearls - National Institutes of Health (NIH) StatPearls Publishing

Frequently Asked Questions (FAQ)

Common questions about Ketamidor (FAQ)


Q: What is the difference between Ketamidor and its active ingredient?

Ketamidor is the brand name used for the drug. The active ingredient in the solution for injection, as described in official product information, is ketamine (as hydrochloride), which belongs to the class of dissociative anesthetics.


Q: Does Ketamidor have a boxed warning in official documents?

Official labeling for the active ingredient does not typically include a single Boxed Warning. However, the official label does contain numerous prominent warnings concerning safety risks, such as rapid changes in blood pressure, emergence reactions (psychological effects upon recovery), and potential neurotoxicity in very young children.


Q: Is Ketamidor a type of painkiller or something else?

Ketamidor is officially classified as a dissociative anesthetic. It is primarily indicated for the induction and maintenance of general anesthesia during diagnostic or surgical procedures. Its official classification is as a dissociative anesthetic, not a common over-the-counter painkiller.


Q: Do people take Ketamidor for things other than its main use?

The official drug label describes only the approved use as an anesthetic agent. Governmental health bodies have issued statements concerning compounded versions of the drug being promoted or used for non-approved psychiatric disorders outside of monitored clinical settings.


Q: Is Ketamidor considered a controlled substance?

Yes, in the United States, the drug is classified as a Schedule III non-narcotic controlled substance under the Controlled Substances Act. This classification indicates that while it has accepted medical uses, it also has a potential for abuse.


Q: What are the most common side effects reported with Ketamidor?

Commonly reported reactions are related to the cardiovascular system, such as an elevated heart rate and blood pressure. Reported psychological effects during recovery, known as emergence reactions, may include confusion, vivid dreams, or feeling 'out of it.'


Q: Is it normal to feel tired after taking Ketamidor?

Postoperative confusional states are noted during recovery. The feeling of tiredness or other CNS effects upon emergence is consistent with the central nervous system effects described in official product information.


Q: Are there any serious side effects I need to know about?

Official warnings cover serious concerns such as respiratory depression (slowed or stopped breathing), changes in heart rhythm, and significant fluctuations in blood pressure, all of which are conditions that require continuous monitoring during administration.


Q: Can Ketamidor be taken with common over-the-counter pain relievers?

Official warnings specifically advise caution when Ketamidor is used with other medicines that cause sedation, such as opioids or benzodiazepines, as this can increase the risk of respiratory depression. Information regarding common non-opioid, over-the-counter pain relievers is not typically highlighted in official product labeling.


Q: What kind of foods or drinks interact with Ketamidor?

Official labeling advises against alcohol consumption for patients receiving the drug. Furthermore, some regulatory documents have noted that certain foods or drinks, such as grapefruit juice, may potentially affect the concentration of the drug in the body.


Q: Is it safe to drink alcohol while using Ketamidor?

Official documents advise against the consumption of alcohol while receiving the drug. Caution is also advised when the drug is administered to patients who are acutely intoxicated or have a history of chronic alcoholism.


Q: Can older adults use Ketamidor?

Yes, official labeling includes guidance for its use in the geriatric population. This reflects that official guidance suggests caution in dosing for this population, due to the greater frequency of decreased organ function in older adults.


Q: Is Ketamidor safe for people with kidney problems?

The drug is primarily removed from the body through the kidneys. Official documents emphasize the need for caution, which reflects considerations for individuals with decreased renal function.


Q: Are there special considerations for people with liver disease and Ketamidor?

Official product information notes that drug-induced liver injury has been associated with administration, and caution is advised. Dosing may require adjustment in individuals with known liver issues.


Q: Can pregnant or breastfeeding individuals take Ketamidor?

Official guidance indicates that safe use during pregnancy, labor, and delivery has not been established. Use during breastfeeding is also generally advised against due to limited data on excretion into human milk and its effect on the breastfed infant.


Q: Is Ketamidor habit-forming or addictive?

As a Schedule III substance, the drug is noted to have a potential for abuse. Official labeling states that abuse may lead to a high potential for psychological dependence and a moderate to low potential for physical dependence.


Q: What should I do if the side effects seem severe?

Official documents outline which severe symptoms (e.g., severe respiratory depression, hemodynamic instability) require immediate medical management. These are conditions that are managed by the physician attending the procedure.


Q: Will Ketamidor affect my ability to drive or operate machinery?

Official patient counseling information advises avoiding hazardous activities requiring complete mental alertness and motor coordination, such as driving or operating machinery, for at least 24 hours following administration.


Q: How long does Ketamidor stay in your system after stopping?

The drug's elimination half-life is described in pharmacokinetic data as approximately 2.5 to 3 hours, which is the time it takes for half the drug to be removed from the body.


Q: Why do some people say Ketamidor makes them feel 'out of it'?

The drug is classified as a dissociative anesthetic. Its use is associated with 'emergence reactions' or 'dissociative states,' which can include feeling detached, having vivid imagery, or entering dream-like states.


Q: What is the typical duration of treatment with Ketamidor?

Ketamidor is indicated only for use as an anesthetic agent during diagnostic and surgical procedures. Official documents define its role as an acute, short-duration intervention, not a long-term treatment.


Q: Can I take Ketamidor if I have a history of heart issues?

The drug is contraindicated in people who have conditions where a significant increase in blood pressure would create a serious risk. Patients with conditions like high blood pressure or other cardiac issues are noted as requiring continuous, careful monitoring during the procedure.


Q: Is Ketamidor effective for chronic conditions?

The approved indications for Ketamidor are limited to its use as an anesthetic agent for diagnostic and surgical procedures. It is not approved for the long-term or chronic management of conditions.


Q: How is Ketamidor stored?

Official product information states that the drug is typically stored at a controlled room temperature (e.g., 20 C to 25 C), with excursions permitted, and should be protected from light.


Q: Is there a generic version of Ketamidor available?

The active ingredient, ketamine, is available as a generic drug (Ketamine Hydrochloride Injection) alongside its various brand-name products, subject to local regulatory approval and availability.


Q: Are headaches a common side effect of Ketamidor?

While headaches are sometimes reported as adverse reactions in clinical trial data, official product information does not typically list them among the most frequent or prominent side effects of the anesthetic.


Q: Can Ketamidor cause mood changes or depression?

The drug can cause temporary psychological effects during emergence, such as confusion and irrational behavior. Severe symptoms, including depression, have been reported in the context of chronic use, which is not an approved use.


Q: What conditions make someone ineligible to use Ketamidor?

Official contraindications for use include known hypersensitivity to the drug and any pre-existing condition, such as uncontrolled high blood pressure, where an elevation in blood pressure would constitute a serious hazard.


Q: Why is Ketamidor sometimes discussed online in non-medical contexts?

Because the drug is classified as a Schedule III controlled substance with dissociative effects, official documents note that it carries a potential for abuse, leading to its mention in non-medical and recreational online discussions.


Q: What kind of monitoring is needed while taking Ketamidor?

Continuous monitoring of vital signs and cardiac function is required during its use. Emergency equipment for airway support must also be immediately available, consistent with its role as an anesthetic.


Q: Does Ketamidor affect sleep patterns?

The drug's effects on the central nervous system, including the potential for postoperative confusion and altered psychological states, may temporarily affect the normal sleep-wake cycle immediately following administration.


Q: Are there any age restrictions for using Ketamidor?

The drug is generally considered suitable for use in pediatric patients. However, official warnings note potential developmental neurotoxicity if the drug is used for extended periods (longer than three hours) in children three years of age and younger.


Q: Can people with high blood pressure use Ketamidor?

Official product information states that the drug is contraindicated for individuals with uncontrolled or untreated high blood pressure because of its potential to elevate blood pressure.


Q: Is there a risk of overdose with Ketamidor?

Yes, official product information warns that an overdose, or too rapid an administration, can lead to severe respiratory depression (difficulty breathing), which requires immediate medical support and management.


Q: What if Ketamidor doesn't seem to be working for me?

The dosage is individualized and titrated to the desired clinical effect by the physician. If a longer duration is required, additional amounts can be administered under direct physician supervision.


Q: Are there known long-term side effects of taking Ketamidor?

Ketamidor is intended for acute, short-term anesthetic use. Official warnings address potential long-term cognitive deficits if the drug is used for extended periods in very young children. Chronic off-label use has been associated with genitourinary symptoms.


Q: Is Ketamidor used in other countries besides the US?

Yes, the drug is approved and used in numerous countries globally. Regulatory documents from major international bodies, such as the European Medicines Agency (EMA), indicate its approved use in many international jurisdictions.


Q: Does Ketamidor have any known effects on fertility?

Published animal studies indicate that the drug may cause adverse effects on fertility. However, official product information states that the human relevance of these nonclinical findings is uncertain.


Q: Is Ketamidor a steroid?

No, Ketamidor is officially classified as a dissociative anesthetic. It is structurally and functionally distinct from the class of medicines known as steroids.


Q: Does Ketamidor interact with any other medicines?

Official labeling contains specific warnings about its use with other medicines that slow down brain activity (CNS depressants), such as opioid analgesics or benzodiazepines, which can increase the risk of severe side effects like respiratory depression.


Q: Who can and cannot use Ketamidor?

Official documents outline that use is contraindicated (not permitted) for those with drug hypersensitivity or uncontrolled high blood pressure. Official regulatory documents provide descriptions of its use in specific populations, including the elderly, children, and those with pre-existing heart or kidney conditions.

How should Ketamidor be stored and disposed of?

How to Store and Dispose of Ketamidor?

Regulatory information dictates strict guidelines for the storage and disposal of Ketamidor (Ketamine Solution for Injection) to ensure product integrity and safety.

️ Storage Requirements

Condition Requirement (Official Label)
Temperature Store below 30 C (86 F), typically at controlled room temperature.
Protection Must be protected from light and not frozen.
Container Rule Keep the solution in its original container.
Child Safety Keep out of reach of children.

⏳ Stability and Handling

Ketamidor is intended for single use only. Once diluted or prepared, the solution should be used immediately from a microbiological perspective, and any unused remaining portion must be discarded.

️ Disposal Instructions

Disposal of unused or expired product and any related waste material must be conducted in accordance with local requirements. The official process requires that product waste avoid release to the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ketamidor found in:

A-Z Index: